cbdMD (YCBD) Income from Continuing Operations (2016 - 2026)
cbdMD (YCBD) posted Income from Continuing Operations of 283131.0 for Q4 2025, up 58.36% sequentially from 679968.0 in Q3 2025, and down 1975.66% YoY from 15095.0 in Q4 2024.
cbdMD (YCBD) Income from Continuing Operations (2016 - 2026) Analysis & Trends
cbdMD has reported Income from Continuing Operations for 10 years, with the latest figure at 283131.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 1975.66% year-over-year to 283131.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2339128.0 (up 13.0% YoY) and the FY2025 annual result came in at 2040902.0, up 44.84% from the prior year.
- Income from Continuing Operations rose to 283131.0 in Q4 2025 per YCBD's latest filing, from 679968.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1537288.0 in Q2 2021 and troughed at 31634143.0 in Q2 2022.
- A 5-year average of 5696964.9 and a median of 1553603.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations sank 2157.79% in 2022, then surged 125.97% in 2024.
- Over 5 years, Income from Continuing Operations stood at 19160904.0 in 2021, then surged by 79.35% to 3956062.0 in 2022, then surged by 74.81% to 996501.0 in 2023, then soared by 101.51% to 15095.0 in 2024, then slumped by 1975.66% to 283131.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 283131.0, 679968.0, and 895272.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | -1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.13 Mn |
| Dec 31, 2025 | -283,131.00 |
| Sep 30, 2025 | -679,968.00 |
| Jun 30, 2025 | -895,272.00 |
| Mar 31, 2025 | -480,757.00 |
| Dec 31, 2024 | 15,095.00 |
| Sep 30, 2024 | -152,799.00 |
| Jun 30, 2024 | 459,737.00 |
| Mar 31, 2024 | -3.01 Mn |
| Dec 31, 2023 | -996,501.00 |
| Sep 30, 2023 | -15.87 Mn |
| Jun 30, 2023 | -1.77 Mn |
| Mar 31, 2023 | -1.34 Mn |
| Dec 31, 2022 | -3.96 Mn |
| Sep 30, 2022 | -14.63 Mn |
| Jun 30, 2022 | -31.63 Mn |
| Mar 31, 2022 | -4.66 Mn |
| Dec 31, 2021 | -19.16 Mn |
| Sep 30, 2021 | -3.92 Mn |
| Jun 30, 2021 | 1.54 Mn |